Skip to content
Publications
You are here:
- Home
- Publications
-
Napieralski R, et al. Establishment of a RESEARCH USE ONLY Condensed-Efficient-Fast (CEF) PITX2 workflow for analysis of PITX2 DNA methylation in small tumor tissue samples. Nature Protocol Exchange doi:10.21203/rs.2.20624/v1 (2020).
-
Schricker, G. et al. Clinical performance of an analytically validated assay in comparison to microarray technology to assess PITX2 DNA-methylation in breast cancer. Scientific Reports 8, 16861, doi:10.1038/s41598-018-34919-1 (2018).
-
Schmitt, M. et al. Clinical validation of PITX2 DNA-methylation as predictor for outcome to anthracycline-based chemotherapy in high-risk breast cancer patients. Breast Care, doi:10.1159/000493016 (2018).
-
Wilhelm, O. G. & Kiechle, M. Prognosis and Prediction in Breast Cancer: Is There a Need for Further Tests? The Journal of Applied Laboratory Medicine 3, 159-162, doi:10.1373/jalm.2018.026161 (2018).
-
Napieralski, R. et al. therascreen PITX2 RGQ PCR assay for the assessment of PITX2 DNA-methylation status to investigate the role of the transcription factor PITX2 and the regulation of the Wnt/ß-catenin pathway in pathophysiological processes. Nature Protocol Exchange, doi: 10.1038/protex.2018.022 (2018).
-
Absmaier, M. et al. PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients. Int J Oncol 52, 755-767, doi:10.3892/ijo.2018.4241 (2018).
-
Uhl, B. et al. PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies. J Mol Diagn 19, 107-114, doi:10.1016/j.jmoldx.2016.08.008 (2017).
-
Aubele, M. et al. The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges. Dis Markers 2017, 4934608, doi:10.1155/2017/4934608 (2017).
-
Wang, Q. et al. Smad4-dependent suppressor pituitary homeobox 2 promotes PPP2R2A-mediated inhibition of Akt pathway in pancreatic cancer. Oncotarget 7, 11208-11222, doi:10.18632/oncotarget.7158 (2016).
-
Uhl, B. et al. DNA Methylation of PITX2 and PANCR Is Prognostic for Overall Survival in Patients with Resected Adenocarcinomas of the Biliary Tract. PLoS One 11, e0165769, doi:10.1371/journal.pone.0165769 (2016).
-
Sailer, V. et al. PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma. Oncotarget 7, 75827-75838, doi:10.18632/oncotarget.12417 (2016).
-
Luan, Z. et al. Prediction efficiency of PITX2 DNA methylation for prostate cancer survival. Genet Mol Res 15, doi:10.4238/gmr.15026750 (2016).
-
Vasiljevic, N. et al. DNA methylation of PITX2 predicts poor survival in men with prostate cancer. Biomark Med 8, 1143-1150, doi:10.2217/bmm.14.41 (2014).
-
Litovkin, K. et al. Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer. J Cancer Res Clin Oncol 140, 1849-1861, doi:10.1007/s00432-014-1738-8 (2014).
-
Dietrich, D. et al. Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. J Mol Diagn 15, 270-279, doi:10.1016/j.jmoldx.2012.11.002 (2013).
-
Dietrich, D. et al. DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients. Diagn Mol Pathol 21, 93-104, doi:10.1097/PDM.0b013e318240503b (2012).
-
Napieralski, R. et al. Emerging biomarkers in breast cancer care. Biomark Med 4, 505-522, doi:10.2217/bmm.10.73 (2010).
-
Banez, L. L. et al. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol 184, 149-156, doi:10.1016/j.juro.2010.03.012 (2010).
-
Weiss, G. et al. DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. J Urol 181, 1678-1685, doi:10.1016/j.juro.2008.11.120 (2009).
-
Martens, J. W. M. et al. DNA methylation as a biomarker in breast cancer. Future Oncol 5, 1245-1256, doi:10.2217/fon.09.89 (2009).
-
Hartmann, O. et al. DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy. Clin Cancer Res 15, 315-323, doi:10.1158/1078-0432.CCR-08-0166 (2009).
-
Duffy, M. J. et al. Methylated genes as new cancer biomarkers. Eur J Cancer 45, 335-346, doi:10.1016/j.ejca.2008.12.008 (2009).
-
Nimmrich, I. et al. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients. Breast Cancer Res Treat 111, 429-437, doi:10.1007/s10549-007-9800-8 (2008).
-
Harbeck, N. et al. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. J Clin Oncol 26, 5036-5042, doi:10.1200/JCO.2007.14.1697 (2008).
-
Maier, S. et al. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients–Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group. Eur J Cancer 43, 1679-1686, doi:10.1016/j.ejca.2007.04.025 (2007).
-
Martens, J. W. et al. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res 65, 4101-4117, doi:10.1158/0008-5472.CAN-05-0064 (2005).
Go to Top